The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in order to determine the most effective surveillance programme for the prevention of colorectal cancer. Over 20,000 participants from a selection of European countries are assigned to one of three EPoS trials depending on the characteristics of their presenting polyps (categorised as high risk, low risk or serrated polyps), following a clinical colonoscopy.
In collaboration with the University of Oslo, Frontier Science designed the randomisation method, developed the eCRF data collection system, and is responsible for ongoing clinical database management, data management and reporting. In addition Frontier Science has recently adapted the randomisation parameters, eCRF data collection system and data management, to incorporate an additional prospective, observational study including patients with cancer polyps removed at colonoscopy, into the portfolio.
